Eluvia Drug Eluting Stent meets primary endpoint in trial for Peripheral Artery Disease-Boston Scientific

In a key trial evaluating the Boston Scientific Eluvia Drug-Eluting Vascular Stent System in the treatment of peripheral artery disease (PAD), the device met its primary endpoint, with more than 94 percent of the lesions treated remaining open at nine months post implantation. This was accompanied by a target lesion revascularization rate of less than four percent. Nine-month data from the MAJESTIC trial demonstrated a primary patency rate of 94.4 percent, a target lesion revascularization rate of 3.6 percent and no deaths or amputations. The trial enrolled 57 patients across Europe, Australia and New Zealand with an average lesion length of 70.8 mm.

The Eluvia Stent System is the first stent purpose-built for the superficial femoral artery that utilizes a polymer and paclitaxel combination designed to facilitate a sustained drug release to reduce restenosis. The Eluvia Stent is built on the Innova Stent System platform consisting of a self-expanding nitinol stent with a paclitaxel-eluting biostable polymer matrix loaded on a low-profile delivery system. Results from the MAJESTIC trial were presented at the 37th Charing Cross International Symposium.